Alimera Sciences Announces Real-World Clinical Data for ILUVIEN® to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference

ATLANTA, Nov. 12, 2020 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that new real-world clinical data for ILUVIEN® will be featured in 3 posters at the American Academy of Ophthalmology 2020 Virtual Conference. The posters will be available to registered attendees beginning Friday, November 13, 2020.

Posters include:

  • Abstract # 30064808: “Outcomes from the prospective IDEAL registry study – results achieved with the 0.2 µg/day fluocinolone acetonide implant” – Khoramnia, et. al.
  • Abstract # 30064802: “Three-year real-world outcomes from the IRISS registry study, using the 0.2 µg/day fluocinolone acetonide (FAc) implant” – Khoramnia, et. al.
  • Abstract # 30065140: “Predictive value IOP challenge and other safety measures of PALADIN 2yr. data” – Malik, et. al.

“ILUVIEN is a uniquely durable therapy, providing physicians the opportunity to reduce the recurrence of diabetic macular edema, and therefore reduce the need for frequent injections of the current standard of care,” said Rick Eiswirth, President and CEO of Alimera.“We are very excited to have these abstracts showcased at the American Academy of Ophthalmology, highlighting the longer term three-year outcomes that support ILUVIEN’s ability to give more DME patients the potential to see better, longer, with fewer injections.”

Registration to the conference can be accessed here.


ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant, injected into the back of the eye. With its CONTINUOUS MICRODOSING™ technology, ILUVIEN is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months, to reduce the recurrence of disease. ILUVIEN enables patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S., Australia, Canada, Kuwait, Lebanon and the U.A.E. to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. ILUVIEN is indicated in 17 European countries for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies and in 16 European countries for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU). Alimera does not have the contractual right to pursue approval to treat uveitis in the U.S., and therefore does not have a regulatory license in the U.S. to treat NIPU. For important safety information on ILUVIEN, see

About Alimera Sciences, Inc.

Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit

Forward Looking Statements

This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s beleif that ILUVIEN reduces the need for frequent injections of the current standard of care. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors include but are not limited to the willingness of physicians to consider ILUVIEN as an alternative to the current standard of care, as well as the factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020, and September 30, 2020 which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at

All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For press inquiries:

Jules Abraham
for Alimera Sciences
[email protected]
For investor inquiries:

Scott Gordon
for Alimera Sciences
[email protected]